Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
16 Results for "
ezh2+protac
" in MedChemExpress (MCE) Product Catalog:
Products (16)
16 Results for "ezh2+protac" in MCE Product Catalog:
Target:
Research Areas:
MS8815 is a EZH2 PROTAC degrader, with a DC50 of 140 nM in MDA-MB-453 triple-negative breast cancer (TNBC) cells and an IC50 of 8.6 nM against human EZH2. MS8815 induces ubiquitin-proteasome system-mediated degradation of EZH2, reduces the levels of EED, SUZ12, FOXM1, H3K27me3 and global m6A, and increases the protein level of HMGCS2. MS8815 can be used in the research of breast cancer and prostate cancer [2] .
Cat. No.: HY-168131
CAS No.: 3098718-46-5
Research Areas:
PROTAC EZH2 Degrader-3 is a EZH2 PROTAC degrader. PROTAC EZH2 Degrader-3 induces the global degradation of the PRC2 complex (including EZH2, SUZ12, EED, RbAp48) via the ubiquitin-proteasome pathway and downregulates H3K27me3 levels. PROTAC EZH2 Degrader-3 inhibits cancer cell proliferation and induces their apoptosis. PROTAC EZH2 Degrader-3 can be used in research related to lymphoblastoma and diffuse large B-cell lymphoma .
Cat. No.: HY-181331
CAS No.: 2653338-70-4
Target:
Research Areas:
PROTAC EZH2 Degrader-27 is a EZH2 PROTAC inhibitor with an IC50 of 4.00 nM against EZH2. PROTAC EZH2 Degrader-27 inhibits methyltransferase activity by interacting with the SET domain of EZH2 .
Cat. No.: HY-181355
CAS No.: 3093642-29-3
Target:
Research Areas:
PROTAC EZH2 Degrader-28 is an EZH2 PROTAC degrader. PROTAC EZH2 Degrader-28 promotes the ubiquitination and degradation of EZH2. PROTAC EZH2 Degrader-28 can be used for lymphoma-related research .
Cat. No.: HY-181360
CAS No.: 3093642-33-9
Target:
Research Areas:
PROTAC EZH2 Degrader-31 is an EZH2 PROTAC degrader. PROTAC EZH2 Degrader-31 promotes the ubiquitination and degradation of EZH2. PROTAC EZH2 Degrader-31 can be used for lymphoma-related research .
Cat. No.: HY-181305
CAS No.: 2653338-60-2
Target:
Research Areas:
PROTAC EZH2 Degrader-10 is a selective PROTAC protein degrader targeting EZH2. PROTAC EZH2 Degrader-10 can be used for the research of cancer .
Cat. No.: HY-181323
CAS No.: 2653338-66-8
Target:
Research Areas:
PROTAC EZH2 Degrader-22 (compound 7) is a PROTAC protein degrader targeting EZH2. PROTAC EZH2 Degrader-22 is applicable to cancer-related research .
Cat. No.: HY-186272
CAS No.: 3050872-64-2
Research Areas:
MS8847N2 is a negative control analog of an EZH2 PROTAC degrader that binds EZH2 but does not bind the VHL E3 ligase or induce EZH2 degradation .
Cat. No.: HY-181301
CAS No.: 3093642-34-0
Target:
Research Areas:
PROTAC EZH2 Degrader-18 (compound E-CH2-B4) is a PROTAC protein degrader targeting EZH2. PROTAC EZH2 Degrader-18 is applicable to lymphoma-related research .
Cat. No.: HY-181333
CAS No.: 2653338-74-8
Target:
Research Areas:
PROTAC EZH2 Degrader-38 (Compound 17) is a EZH2 PROTAC degrader with an IC50 of 165.00 nM. PROTAC EZH2 Degrader-38 functionally inhibits the methyltransferase activity of EZH2 and competitively binds to the SAM-binding pocket of the EZH2 SET domain .
Cat. No.: HY-181326
CAS No.: 2653338-69-1
Target:
Research Areas:
PROTAC EZH2 Degrader-25 (compound 10) is an EZH2-targeting PROTAC degrader. PROTAC EZH2 Degrader-25 triggers ubiquitination and subsequent proteasomal degradation of EZH2. PROTAC EZH2 Degrader-25 can be used for the research of lymphoma .
Cat. No.: HY-160423
CAS No.: 2855085-26-4
Target:
Research Areas:
MS8815N is a negative control of EZH2 PROTAC degrader MS8815 (HY-148334). MS8815N is incapable of recruiting the VHL E3 ligase but retains the same EZH2 binding moiety and linker. MS8815N can be used for triple-negative breast cancer (TNBC) research .
Cat. No.: HY-181411
CAS No.: 3093642-42-0
Target:
Research Areas:
PROTAC EZH2 Degrader-42 (compound 57) is an EZH2-targeting PROTAC degrader and antiproliferative agent. PROTAC EZH2 Degrader-42 induces cIAP-mediated ubiquitination and subsequent proteasomal degradation of EZH2. PROTAC EZH2 Degrader-42 can be used for the research of lymphoma .
Cat. No.: HY-181295
CAS No.: 3093642-21-5
Target:
Research Areas:
PROTAC EZH2 Degrader-14 is an EZH2 PROTAC degrader, with an IC50 of 18.21 μM against diffuse large B-cell lymphoma cells, and exhibits no antiproliferative activity against non-target cells at concentrations up to 30.00 μM. PROTAC EZH2 Degrader-14 can be used in studies related to diffuse large B-cell lymphoma .
Cat. No.: HY-181327
CAS No.: 2641601-66-1
Target:
Research Areas:
PROTAC EZH2 Degrader-26 (compound 11) is an EZH2 degrader developed based on PROTAC technology. PROTAC EZH2 Degrader-26 has an IC50 of 5.80 nM against EZH2. PROTAC EZH2 Degrader-26 exhibits micromolar-level enzyme inhibitory activity against EZH1, with an EZH1 IC50 of 0.06 μM .
Cat. No.: HY-179499
CAS No.: 2978620-84-5
Research Areas:
PROTAC EZH2 Degrader-9 is orally active EZH2 PROTAC degrader degrading EZH2 via the ubiquitin-proteasome pathway. PROTAC EZH2 Degrader-9 downregulates PRC2 core subunits and potent inhibition of H3K27me3 without affecting common CRBN neosubstrates while it was selective over GSp'T1 and ikZF1/3. PROTAC EZH2 Degrader-9 exhibits potent antiproliferative activity against multiple cancer cell lines by inducing cell cycle and apoptosis. PROTAC EZH2 Degrader-9 reverses PRC2-mediated gene silencing and inhibiting EZH2 non-catalytic target gene activation. PROTAC EZH2 Degrader-9 can be used for leukemia, lymphoma, and non-small cell lung cancer research .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
